Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Facial Plastic Surgery : FPS
|
December 30, 2011
Neuromodulators: available agents, physiology, and anatomy
Kartik Nettar, Corey Maas
Facial Plastic Surgery : FPS
|
June 23, 2012
Facial filler and neurotoxin complications
Kartik Nettar, Corey Maas
Facial Plastic Surgery Clinics of North America
|
October 8, 2023
Neuromodulators for Skin
Anya Costeloe, Angela Nguyen, Corey Maas
Aesthetic Surgery Journal
|
December 1, 2009
An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines
Mark Rubin, Jeffrey Dover, Corey Maas, et al.
Archives of Facial Plastic Surgery
|
March 18, 2009
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines
Ronald Moy, Corey Maas, Gary Monheit, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
July 30, 2019
Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines
Gary D Monheit, Leslie Baumann, Corey Maas, et al.
Journal of Drugs in Dermatology : JDD
|
January 26, 2019
IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A
Martina Kerscher, Rungsima Wanitphakdeedecha, Ada Trindade de Almeida, et al.
Aesthetic Surgery Journal
|
March 22, 2013
Juvederm ultra for lip enhancement: an open-label, multicenter study
Steven Fagien, Corey Maas, Diane K Murphy, et al.
Facial Plastic Surgery & Aesthetic Medicine
|
November 7, 2025
Prevention of Hematoma in Patients Undergoing Facelift (Rhytidectomy): A Systematic Review and Meta-Analysis
Jason Lee Azzi, Armon Hadian, Dorsa Zabihi-Pour, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
November 9, 2020
A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
Joel Schlessinger, Joel L Cohen, Ava Shamban, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Facial Plastic Surgery : FPS
|
December 30, 2011
Neuromodulators: available agents, physiology, and anatomy
Kartik Nettar, Corey Maas
Facial Plastic Surgery : FPS
|
June 23, 2012
Facial filler and neurotoxin complications
Kartik Nettar, Corey Maas
Facial Plastic Surgery Clinics of North America
|
October 8, 2023
Neuromodulators for Skin
Anya Costeloe, Angela Nguyen, Corey Maas
Aesthetic Surgery Journal
|
December 1, 2009
An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines
Mark Rubin, Jeffrey Dover, Corey Maas, et al.
Archives of Facial Plastic Surgery
|
March 18, 2009
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines
Ronald Moy, Corey Maas, Gary Monheit, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
July 30, 2019
Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines
Gary D Monheit, Leslie Baumann, Corey Maas, et al.
Journal of Drugs in Dermatology : JDD
|
January 26, 2019
IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A
Martina Kerscher, Rungsima Wanitphakdeedecha, Ada Trindade de Almeida, et al.
Aesthetic Surgery Journal
|
March 22, 2013
Juvederm ultra for lip enhancement: an open-label, multicenter study
Steven Fagien, Corey Maas, Diane K Murphy, et al.
Facial Plastic Surgery & Aesthetic Medicine
|
November 7, 2025
Prevention of Hematoma in Patients Undergoing Facelift (Rhytidectomy): A Systematic Review and Meta-Analysis
Jason Lee Azzi, Armon Hadian, Dorsa Zabihi-Pour, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
November 9, 2020
A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
Joel Schlessinger, Joel L Cohen, Ava Shamban, et al.
Page
of 3